PET scan to detect hormone therapy resistance in breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced or metastatic breast cancer that is ER-positive, PR-positive, and HER2-negative.
- You are about to start a new standard endocrine therapy (hormone-blocking treatment).
- If your cancer has spread to your bones, the spots are 'lytic' or 'mixed lytic-sclerotic' (holes or mixed bone changes).
- Your cancer is not only in your liver, and you do not have active brain metastases.
- You are willing to have a PET/CT scan and can lie flat for it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests a special PET scan (a type of imaging) to look at newly diagnosed ER-positive breast cancer. The goal is to see how well the scan can detect and measure cancer, which may help guide care.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This trial is studying if a special PET/MRI scan using a tracer called 18F FES can help doctors decide the best treatment for people with Luminal A or hormone-receptor-positive lobular breast cancer. The scan looks at estrogen receptors to see if your cancer might respond to hormone therapy.
This study tests whether a new type of PET/MRI scan can help doctors see how well breast cancer treatment is working. It is a platform study, meaning it can evaluate different treatments, but the focus is on using this advanced imaging to monitor response.
This study tests whether a special PET scan can better detect invasive lobular breast cancer that has spread. It may help doctors see the cancer more clearly and guide treatment decisions.
This trial tests a new type of PET scan using a special tracer (FAPI) to find cancer spread in people with lobular breast cancer when the standard scan was not clear. The goal is to see if this scan can spot more metastatic lesions, which may help guide treatment.
Hear when a new Metastatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.